Export financials
Opiant Pharmaceuticals (OPNT)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Opiant Pharmaceuticals Income Statement 2021-2005 | OPNT
Brief overview of financial results at Opiant Pharmaceuticals
The comparison covers a five-year financial horizon. The revenue attributed to Opiant Pharmaceuticals moved from 14.8 million dollars to 47.8 million dollars between the two endpoints. Across the full period, sales moved by +222.2%; the average annual rate was 26.4%. This pace points to rapid expansion of the business.
The five-year EBITDA result moved by −54.5%: from 11.5 million dollars to 5.3 million dollars. Changes in revenue did not translate into comparable EBITDA performance. The EBITDA share of revenue changed from 77.8% to 11%. A lower EBITDA share weakens the quality of the result.
The five-year change in net income was −73.9%: from $11.5 million to $3 million. The decline reduces the quality of the financial trajectory.
The market value of the business moved from $15.1 million to $117 million, or +672.4%. The valuation may already include demanding future expectations.
Conclusion
The financial profile remains mixed, with strengths and risks moving in different directions. Key strengths include sales growth. The main areas of concern are lower net income and weaker operating efficiency. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Opiant Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
117 M | 53.8 M | 47.2 M | 45.6 M | 44.5 M | 15.1 M | 16.3 M | 17.9 M | 7.16 M | 5.19 M | 5.37 M | - | - | - | - | - | - |
Shares |
4.46 M | 4.25 M | 4.02 M | 2.99 M | 2.08 M | 1.91 M | 1.81 M | 1.75 M | 143 M | 104 M | 67.2 M | - | - | - | - | - | - |
Historical Prices |
26.2 | 12.7 | 11.8 | 15.3 | 21.4 | 7.9 | 9.01 | 10.2 | 0.05 | 0.05 | 0.08 | - | - | - | - | - | - |
Net Income |
3.01 M | -1.86 M | 11.6 M | -21.2 M | 1.38 M | 11.5 M | -7.04 M | -11.5 M | -9.18 M | -12.4 M | -9.44 M | -2.02 M | 28.4 K | -17.9 K | -33.6 K | -32.1 K | - |
Revenue |
47.8 M | 29.6 M | 40.5 M | 14 M | 11.8 M | 14.8 M | 1.55 M | - | - | 173 M | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | 13.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | 23.4 M | 32.8 M | 12.5 M | - | - | 1.55 M | - | - | 134 M | - | - | - | - | - | - | - |
Operating Income |
5.16 M | -2.24 M | 10.9 M | -21.2 M | 1.54 M | 11.5 M | -6.9 M | -11.3 M | -8.81 M | -12.3 M | -9.44 M | - | - | - | - | - | - |
Interest Expense |
2.13 M | 131 K | - | 145 K | 10.4 K | -11.9 K | 28.2 K | 160 K | 553 K | 61.4 K | - | - | - | - | - | - | - |
EBITDA |
5.25 M | -2.12 M | 11 M | -21.2 M | 1.54 M | 11.5 M | -6.9 M | -11.3 M | -8.81 M | -12.3 M | -9.43 M | - | - | - | - | - | - |
Operating Expenses |
42.6 M | 31.9 M | 29.6 M | 35.2 M | 10.2 M | 3.29 M | 8.45 M | 11.3 M | 8.81 M | 12.3 M | 9.44 M | - | - | - | - | - | - |
General and Administrative Expenses |
12.2 M | 11.7 M | 12.2 M | 11.5 M | 5.89 M | 1.85 M | 6.03 M | 10.8 M | 8.52 M | 11.8 M | 9.44 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Opiant Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 5.14 M | 5.09 M | 5.02 M | 4.91 M | 4.46 M | 4.33 M | 4.28 M | 4.26 M | 4.26 M | 4.26 M | 4.22 M | 4.19 M | 4.05 M | 4 M | 3.91 M | 3.85 M | 2.87 M | 2.68 M | 2.54 M | 2.01 M | 2.01 M | 2.01 M | 1.99 M | 1.88 M | 1.92 M | 1.88 M | 1.85 M | 1.81 M | 1.83 M | 1.81 M | 179 M | 1.71 M | 178 M | 171 M | 166 M | 132 M | 133 M | 132 M | 128 M | 92.8 M | 97.9 M | 92.8 M | 84.9 M | 62.7 M | 84.9 M | 62.7 M | 84.9 M |
Net Income |
- | -9.92 M | -11.7 M | -12.2 M | - | 3.42 M | 1.68 M | -2.84 M | - | 725 K | -216 K | -1.68 M | - | 10.7 M | 1.58 M | -1.74 M | - | -918 K | -1.4 M | -9.34 M | 10.6 M | -3.13 M | 10.6 M | -601 K | 3.97 M | 416 K | 3.97 M | -11.1 M | -2.78 M | -1.85 M | -2.78 M | -775 K | -5.06 M | -554 K | -5.06 M | -1.71 M | -6.29 M | -1.1 M | -567 K | -1.1 M | -4.58 M | -1.47 M | -4.58 M | -4.72 M | -995 K | -4.72 M | -9.44 M | -4.72 M |
Revenue |
- | 174 K | 3.89 M | 4.47 M | - | 16.3 M | 11.3 M | 6.39 M | - | 9.11 M | 6.31 M | 4.28 M | - | 20.6 M | 6.78 M | 5.44 M | - | 4.37 M | 3.15 M | 1.7 M | 13.5 M | 18.1 K | 13.5 M | 1.12 M | 6.86 M | 2.61 M | 6.86 M | 120 K | 560 K | 120 K | 560 K | 120 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | -9.63 M | -11.4 M | -11.8 M | - | 3.96 M | 2.25 M | -2.32 M | - | 727 K | -232 K | -1.72 M | - | 10.6 M | 1.41 M | -1.83 M | - | -940 K | -1.32 M | -9.31 M | 10.6 M | -3.17 M | 10.6 M | -579 K | 4 M | 412 K | 4 M | -11.1 M | -2.77 M | -1.84 M | -2.77 M | -760 K | -5.09 M | -547 K | -5.09 M | -1.54 M | -6.24 M | -857 K | -518 K | -972 K | -4.57 M | -1.45 M | -4.57 M | -4.71 M | -995 K | -4.71 M | -1.28 M | -4.71 M |
Interest Expense |
- | 391 K | 401 K | 421 K | - | 547 K | 542 K | 537 K | - | 3.92 K | 11.5 K | 76.6 K | - | 112 K | 122 K | 122 K | - | 20 K | 6 K | 5 K | 877 | 10.7 K | 877 | -2.24 K | 5.49 K | -2 K | 5.49 K | 5.83 K | 19.4 K | 4.1 K | 19.4 K | 8.21 K | 6.24 K | 7.25 K | 6.24 K | 126 K | 109 K | 177 K | 98.5 K | 145 K | 3 K | 3 K | 3 K | 13.5 K | - | 13.5 K | - | 13.5 K |
EBITDA |
- | -9.6 M | -11.3 M | -11.8 M | - | 4.04 M | 2.31 M | -2.29 M | - | 819 K | -171 K | -1.68 M | - | 10.6 M | 1.42 M | -1.83 M | - | -938 K | -1.32 M | -9.31 M | 10.6 M | -3.16 M | 10.6 M | -578 K | 4 M | 413 K | 4 M | -11.1 M | -2.77 M | -1.84 M | -2.77 M | -760 K | -5.09 M | -546 K | -5.09 M | -1.54 M | -6.24 M | -856 K | -518 K | -971 K | -4.57 M | -1.45 M | -4.57 M | -4.71 M | -995 K | -4.71 M | -1.28 M | -4.71 M |
Operating Expenses |
- | 9.8 M | 15.3 M | 16.3 M | - | 12.4 M | 9.01 M | 8.71 M | - | 8.38 M | 6.54 M | 6 M | - | 10 M | 5.36 M | 7.26 M | - | 5.31 M | 4.47 M | 11 M | 2.9 M | 3.18 M | 2.9 M | 1.7 M | 2.86 M | 2.19 M | 2.86 M | 11.2 M | 3.33 M | 1.96 M | 3.33 M | 760 K | 5.09 M | 547 K | 5.09 M | 1.54 M | 6.24 M | 857 K | 518 K | 972 K | 4.57 M | 1.45 M | 4.57 M | 4.71 M | 995 K | 4.71 M | 1.28 M | 4.71 M |
General and Administrative Expenses |
- | 3.07 M | 4.01 M | 4.33 M | - | 3.38 M | 2.73 M | 2.65 M | - | 2.73 M | 2.84 M | 2.57 M | - | 3.21 M | 3.73 M | 3.7 M | - | 3.4 M | 2.86 M | 2.96 M | 1.36 M | 2 M | 1.36 M | 1.22 M | 2.39 M | 1.13 M | 2.49 M | 10.8 M | 2.14 M | 1.86 M | 2.14 M | 708 K | 5.06 M | 494 K | 5.06 M | 1.48 M | 6.17 M | 822 K | 444 K | 923 K | 4.52 M | 1.45 M | 4.57 M | 4.71 M | 995 K | 4.41 M | 1.28 M | 4.71 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Opiant Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.